{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:47:24Z","timestamp":1784666844132,"version":"3.55.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.7759\/cureus.95908","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:43:19Z","timestamp":1762015399000},"source":"Crossref","is-referenced-by-count":1,"title":["Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas Unleashed: Transforming Gene Editing With Breakthroughs, Applications, and Ethical Dilemmas"],"prefix":"10.7759","author":[{"given":"Balasundari","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adegbenro O","family":"Fakoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2022.102876","article-title":"Clustered regularly interspaced short palindromic repeats\/CRISPR-associated protein and hairy roots: a perfect match for gene functional analysis and crop improvement","volume":"79","author":"Alamillo JM","year":"2023","unstructured":"Alamillo JM, L\u00f3pez CM, Mart\u00ednez Rivas FJ, Torralbo F, Bulut M, Alseekh S. Clustered regularly interspaced short palindromic repeats\/CRISPR-associated protein and hairy roots: a perfect match for gene functional analysis and crop improvement. Curr Opin Biotechnol. 2023, 79:102876. 10.1016\/j.copbio.2022.102876","journal-title":"Curr Opin Biotechnol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li T","year":"2023","unstructured":"Li T, Yang Y, Qi H, et al.. CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023, 8:36. 10.1038\/s41392-023-01309-7","journal-title":"Signal Transduct Target Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.02.027","article-title":"Clinical applications of the CRISPR\/Cas9 genome-editing system: delivery options and challenges in precision medicine","volume":"11","author":"Khoshandam M","year":"2024","unstructured":"Khoshandam M, Soltaninejad H, Mousazadeh M, Hamidieh AA, Hosseinkhani S. Clinical applications of the CRISPR\/Cas9 genome-editing system: delivery options and challenges in precision medicine. Genes Dis. 2024, 11:268-82. 10.1016\/j.gendis.2023.02.027","journal-title":"Genes Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li H","year":"2020","unstructured":"Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020, 5:1. 10.1038\/s41392-019-0089-y","journal-title":"Signal Transduct Target Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.155","article-title":"Current landscape of gene-editing technology in biomedicine: applications, advantages, challenges, and perspectives","volume":"3","author":"Zhou W","year":"2022","unstructured":"Zhou W, Yang J, Zhang Y, Hu X, Wang W. Current landscape of gene-editing technology in biomedicine: applications, advantages, challenges, and perspectives. MedComm (2020). 2022, 3:e155. 10.1002\/mco2.155","journal-title":"MedComm (2020)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/07388551.2022.2092714","article-title":"Engineering traits through CRISPR\/cas genome editing in woody species to improve forest diversity and yield","volume":"43","author":"Thapliyal G","year":"2023","unstructured":"Thapliyal G, Bhandari MS, Vemanna RS, Pandey S, Meena RK, Barthwal S. Engineering traits through CRISPR\/cas genome editing in woody species to improve forest diversity and yield. Crit Rev Biotechnol. 2023, 43:884-903. 10.1080\/07388551.2022.2092714","journal-title":"Crit Rev Biotechnol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081103","article-title":"CRISPR-Cas system: the current and emerging translational landscape","volume":"12","author":"Bhokisham N","year":"2023","unstructured":"Bhokisham N, Laudermilch E, Traeger LL, Bonilla TD, Ruiz-Estevez M, Becker JR. CRISPR-Cas system: the current and emerging translational landscape. Cells. 2023, 12:1103. 10.3390\/cells12081103","journal-title":"Cells"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061813","article-title":"The potential revolution of cancer treatment with CRISPR technology","volume":"15","author":"Stefanoudakis D","year":"2023","unstructured":"Stefanoudakis D, Kathuria-Prakash N, Sun AW, et al.. The potential revolution of cancer treatment with CRISPR technology. Cancers (Basel). 2023, 15:1813. 10.3390\/cancers15061813","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00247-9","article-title":"Genome editing using CRISPR\/Cas9 to treat hereditary hematological disorders","volume":"29","author":"Chen Y","year":"2022","unstructured":"Chen Y, Wen R, Yang Z, Chen Z. Genome editing using CRISPR\/Cas9 to treat hereditary hematological disorders. Gene Ther. 2022, 29:207-16. 10.1038\/s41434-021-00247-9","journal-title":"Gene Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2023.1259435","article-title":"Biomaterials-mediated CRISPR\/Cas9 delivery: recent challenges and opportunities in gene therapy","volume":"11","author":"Dubey AK","year":"2023","unstructured":"Dubey AK, Mostafavi E. Biomaterials-mediated CRISPR\/Cas9 delivery: recent challenges and opportunities in gene therapy. Front Chem. 2023, 11:1259435. 10.3389\/fchem.2023.1259435","journal-title":"Front Chem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084206","article-title":"Application of CRISPR\/Cas9 in crop quality improvement","volume":"22","author":"Liu Q","year":"2021","unstructured":"Liu Q, Yang F, Zhang J, et al.. Application of CRISPR\/Cas9 in crop quality improvement. Int J Mol Sci. 2021, 22:4206. 10.3390\/ijms22084206","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216241","article-title":"CRISPR variants for gene editing in plants: biosafety risks and future directions","volume":"24","author":"Movahedi A","year":"2023","unstructured":"Movahedi A, Aghaei-Dargiri S, Li H, Zhuge Q, Sun W. CRISPR variants for gene editing in plants: biosafety risks and future directions. Int J Mol Sci. 2023, 24:16241. 10.3390\/ijms242216241","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4324\/9781003056034-20","article-title":"Chapter 15: Designer mosquitoes? Prospects and precautions of genome-edited insects for public health","author":"Rajagopalan RM","year":"2022","unstructured":"Rajagopalan RM. Chapter 15: Designer mosquitoes? Prospects and precautions of genome-edited insects for public health. Mosquitopia: The Place of Pests in a Healthy World. Hall M, Tam\u00efr D (ed): Routledge, New York; 2022. 10.4324\/9781003056034-20"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.007034","article-title":"Chemistry of Class 1 CRISPR-Cas effectors: binding, editing, and regulation","volume":"295","author":"Liu TY","year":"2020","unstructured":"Liu TY, Doudna JA. Chemistry of Class 1 CRISPR-Cas effectors: binding, editing, and regulation. J Biol Chem. 2020, 295:14473-87. 10.1074\/jbc.REV120.007034","journal-title":"J Biol Chem"},{"key":"ref15","article-title":"Genome editing technology and applications with the type I CRISPR system","volume":"3","author":"Yoshimi K","year":"2022","unstructured":"Yoshimi K, Mashimo T. Genome editing technology and applications with the type I CRISPR system. Gene Genome Ed. 2022, 3:100013.","journal-title":"Gene Genome Ed"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw421","article-title":"The CRISPR RNA-guided surveillance complex in Escherichia coli accommodates extended RNA spacers","volume":"44","author":"Luo ML","year":"2016","unstructured":"Luo ML, Jackson RN, Denny SR, et al.. The CRISPR RNA-guided surveillance complex in Escherichia coli accommodates extended RNA spacers. Nucleic Acids Res. 2016, 44:7385-94. 10.1093\/nar\/gkw421","journal-title":"Nucleic Acids Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2024.108070","article-title":"The structural biology of type III CRISPR-Cas systems","volume":"216","author":"Li X","year":"2024","unstructured":"Li X, Han J, Yang J, Zhang H. The structural biology of type III CRISPR-Cas systems. J Struct Biol. 2024, 216:108070. 10.1016\/j.jsb.2024.108070","journal-title":"J Struct Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107295","article-title":"Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms","volume":"300","author":"Ganguly C","year":"2024","unstructured":"Ganguly C, Rostami S, Long K, Aribam SD, Rajan R. Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms. J Biol Chem. 2024, 300:107295. 10.1016\/j.jbc.2024.107295","journal-title":"J Biol Chem"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz1197","article-title":"Type IV CRISPR-Cas systems are highly diverse and involved in competition between plasmids","volume":"48","author":"Pinilla-Redondo R","year":"2020","unstructured":"Pinilla-Redondo R, Mayo-Mu\u00f1oz D, Russel J, Garrett RA, Randau L, S\u00f8rensen SJ, Shah SA. Type IV CRISPR-Cas systems are highly diverse and involved in competition between plasmids. Nucleic Acids Res. 2020, 48:2000-12. 10.1093\/nar\/gkz1197","journal-title":"Nucleic Acids Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04252-2","article-title":"The CRISPR tool kit for genome editing and beyond","volume":"9","author":"Adli M","year":"2018","unstructured":"Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018, 9:1911. 10.1038\/s41467-018-04252-2","journal-title":"Nat Commun"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.09.012","article-title":"Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications","volume":"266","author":"Liu C","year":"2017","unstructured":"Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 2017, 266:17-26. 10.1016\/j.jconrel.2017.09.012","journal-title":"J Control Release"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v3i2.184","article-title":"Application of CRISPR-Cas9 genome editing technology in various fields: a review","volume":"3","author":"Ansori AN","year":"2023","unstructured":"Ansori AN, Antonius Y, Susilo RJ, et al.. Application of CRISPR-Cas9 genome editing technology in various fields: a review. Narra J. 2023, 3:e184. 10.52225\/narra.v3i2.184","journal-title":"Narra J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-310459","article-title":"What is CRISPR\/Cas9?","volume":"101","author":"Redman M","year":"2016","unstructured":"Redman M, King A, Watson C, King D. What is CRISPR\/Cas9?. Arch Dis Child Educ Pract Ed. 2016, 101:213-5. 10.1136\/archdischild-2016-310459","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-016-0427-5","article-title":"CRISPR\/Cas9 immune system as a tool for genome engineering","volume":"65","author":"Hryhorowicz M","year":"2017","unstructured":"Hryhorowicz M, Lipi\u0144ski D, Zeyland J, S\u0142omski R. CRISPR\/Cas9 immune system as a tool for genome engineering. Arch Immunol Ther Exp (Warsz). 2017, 65:233-40. 10.1007\/s00005-016-0427-5","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S326422","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","volume":"15","author":"Asmamaw M","year":"2021","unstructured":"Asmamaw M, Zawdie B. Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biologics. 2021, 15:353-61. 10.2147\/BTT.S326422","journal-title":"Biologics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.11.016","article-title":"Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment","volume":"10","author":"Zhou Q","year":"2022","unstructured":"Zhou Q, Chen Y, Wang R, Jia F, He F, Yuan F. Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment. Genes Dis. 2022, 10:2414-24. 10.1016\/j.gendis.2022.11.016","journal-title":"Genes Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering9070291","article-title":"Engineering CRISPR\/Cas13 system against RNA viruses: from diagnostics to therapeutics","volume":"9","author":"Xue Y","year":"2022","unstructured":"Xue Y, Chen Z, Zhang W, Zhang J. Engineering CRISPR\/Cas13 system against RNA viruses: from diagnostics to therapeutics. Bioengineering (Basel). 2022, 9:291. 10.3390\/bioengineering9070291","journal-title":"Bioengineering (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2023.12.018","article-title":"CRISPR therapy of sickle cell disease: the dawning of the gene editing era","volume":"137","author":"Adashi EY","year":"2024","unstructured":"Adashi EY, Gruppuso PA, Cohen IG. CRISPR therapy of sickle cell disease: the dawning of the gene editing era. Am J Med. 2024, 137:390-2. 10.1016\/j.amjmed.2023.12.018","journal-title":"Am J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.31486\/toj.18.0044","article-title":"Curative therapies for sickle cell disease","volume":"19","author":"Khemani K","year":"2019","unstructured":"Khemani K, Katoch D, Krishnamurti L. Curative therapies for sickle cell disease. Ochsner J. 2019, 19:131-7. 10.31486\/toj.18.0044","journal-title":"Ochsner J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002478","article-title":"CRISPR\/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review","volume":"86","author":"Tariq H","year":"2024","unstructured":"Tariq H, Khurshid F, Khan MH, et al.. CRISPR\/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review. Ann Med Surg (Lond). 2024, 86:5938-46. 10.1097\/MS9.0000000000002478","journal-title":"Ann Med Surg (Lond)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101185","article-title":"Revolutionising healing: gene editing's breakthrough against sickle cell disease","volume":"65","author":"Dimitrievska M","year":"2024","unstructured":"Dimitrievska M, Bansal D, Vitale M, et al.. Revolutionising healing: gene editing's breakthrough against sickle cell disease. Blood Rev. 2024, 65:101185. 10.1016\/j.blre.2024.101185","journal-title":"Blood Rev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul H","year":"2024","unstructured":"Frangoul H, Locatelli F, Sharma A, et al.. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024, 390:1649-62. 10.1056\/NEJMoa2309676","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944204","article-title":"First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia","volume":"30","author":"Parums DV","year":"2024","unstructured":"Parums DV. First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia. Med Sci Monit. 2024, 30:e944204. 10.12659\/MSM.944204","journal-title":"Med Sci Monit"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00286-w","article-title":"PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells","volume":"3","author":"Hiramoto T","year":"2023","unstructured":"Hiramoto T, Kashiwakura Y, Hayakawa M, et al.. PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells. Commun Med (Lond). 2023, 3:56. 10.1038\/s43856-023-00286-w","journal-title":"Commun Med (Lond)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00654-5","article-title":"Targeted gene insertion: the cutting edge of CRISPR drug development with hemophilia as a highlight","volume":"38","author":"Zhang Z","year":"2024","unstructured":"Zhang Z, Zhang S, Wong HT, Li D, Feng B. Targeted gene insertion: the cutting edge of CRISPR drug development with hemophilia as a highlight. BioDrugs. 2024, 38:369-85. 10.1007\/s40259-024-00654-5","journal-title":"BioDrugs"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.17179\/excli2023-6155","article-title":"CRISPR\/Cas9 genome editing for neurodegenerative diseases","volume":"22","author":"Nouri Nojadeh J","year":"2023","unstructured":"Nouri Nojadeh J, Bildiren Eryilmaz NS, Erg\u00fcder BI. CRISPR\/Cas9 genome editing for neurodegenerative diseases. EXCLI J. 2023, 22:567-82. 10.17179\/excli2023-6155","journal-title":"EXCLI J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons","volume":"57","author":"Rajmohan R","year":"2017","unstructured":"Rajmohan R, Reddy PH. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons. J Alzheimers Dis. 2017, 57:975-99. 10.3233\/JAD-160612","journal-title":"J Alzheimers Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13877","article-title":"Advancements in APOE and dementia research: highlights from the 2023 AAIC Advancements: APOE conference","volume":"20","author":"Kloske CM","year":"2024","unstructured":"Kloske CM, Belloy ME, Blue EE, et al.. Advancements in APOE and dementia research: highlights from the 2023 AAIC Advancements: APOE conference. Alzheimers Dement. 2024, 20:6590-605. 10.1002\/alz.13877","journal-title":"Alzheimers Dement"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-0358-9","article-title":"Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease","volume":"15","author":"Williams T","year":"2020","unstructured":"Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease. Mol Neurodegener. 2020, 15:8. 10.1186\/s13024-020-0358-9","journal-title":"Mol Neurodegener"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.03.022","article-title":"CRISPR-Cas9 treatment partially restores amyloid-\u03b2 42\/40 in human fibroblasts with the Alzheimer's disease PSEN 1 M146L mutation","volume":"28","author":"Konstantinidis E","year":"2022","unstructured":"Konstantinidis E, Molisak A, Perrin F, et al.. CRISPR-Cas9 treatment partially restores amyloid-\u03b2 42\/40 in human fibroblasts with the Alzheimer's disease PSEN 1 M146L mutation. Mol Ther Nucleic Acids. 2022, 28:450-61. 10.1016\/j.omtn.2022.03.022","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref41","article-title":"Parkinson's disease: etiology, neuropathology, and pathogenesis","author":"Kouli A","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan WL. Parkinson's disease: etiology, neuropathology, and pathogenesis. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects. Stoker TB, Greenland JC (ed): Codon Publications, Brisbane; 2018."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179241","article-title":"Understanding the potential of genome editing in Parkinson\u2019s disease","volume":"22","author":"Arango D","year":"2021","unstructured":"Arango D, Bittar A, Esmeral NP, et al.. Understanding the potential of genome editing in Parkinson\u2019s disease. Int J Mol Sci. 2021, 22:9241. 10.3390\/ijms22179241","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1223747","article-title":"Development of CRISPR Cas9, spin-off technologies and their application in model construction and potential therapeutic methods of Parkinson's disease","volume":"17","author":"Qu J","year":"2023","unstructured":"Qu J, Liu N, Gao L, Hu J, Sun M, Yu D. Development of CRISPR Cas9, spin-off technologies and their application in model construction and potential therapeutic methods of Parkinson's disease. Front Neurosci. 2023, 17:1223747. 10.3389\/fnins.2023.1223747","journal-title":"Front Neurosci"},{"key":"ref44","article-title":"Amyotrophic lateral sclerosis","author":"Brotman RG","year":"2024","unstructured":"Brotman RG, Moreno-Escobar MC, Joseph J, et al.. Amyotrophic lateral sclerosis. StatPearls (Internet). StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.04.003","article-title":"Novel genome-editing-based approaches to treat motor neuron diseases: promises and challenges","volume":"30","author":"Miccio A","year":"2022","unstructured":"Miccio A, Antoniou P, Ciura S, Kabashi E. Novel genome-editing-based approaches to treat motor neuron diseases: promises and challenges. Mol Ther. 2022, 30:47-53. 10.1016\/j.ymthe.2021.04.003","journal-title":"Mol Ther"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33332-7","article-title":"CRISPR\/Cas9-mediated excision of ALS\/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro","volume":"13","author":"Meijboom KE","year":"2022","unstructured":"Meijboom KE, Abdallah A, Fordham NP, et al.. CRISPR\/Cas9-mediated excision of ALS\/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nat Commun. 2022, 13:6286. 10.1038\/s41467-022-33332-7","journal-title":"Nat Commun"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang JH","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024, 9:78. 10.1038\/s41392-024-01780-w","journal-title":"Signal Transduct Target Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae063","article-title":"A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease","volume":"147","author":"Aldous SG","year":"2024","unstructured":"Aldous SG, Smith EJ, Landles C, et al.. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease. Brain. 2024, 147:1784-98. 10.1093\/brain\/awae063","journal-title":"Brain"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington's disease mouse model","volume":"17","author":"Ekman FK","year":"2019","unstructured":"Ekman FK, Ojala DS, Adil MM, Lopez PA, Schaffer DV, Gaj T. CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington's disease mouse model. Mol Ther Nucleic Acids. 2019, 17:829-39. 10.1016\/j.omtn.2019.07.009","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models","volume":"26","author":"Morelli KH","year":"2023","unstructured":"Morelli KH, Wu Q, Gosztyla ML, et al.. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models. Nat Neurosci. 2023, 26:27-38. 10.1038\/s41593-022-01207-1","journal-title":"Nat Neurosci"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.13.584921","article-title":"Enhancer-targeted CRISPR-activation rescues haploinsufficient autism susceptibility genes","author":"Chen GT","year":"2024","unstructured":"Chen GT, Nair G, Osorio AJ, et al.. Enhancer-targeted CRISPR-activation rescues haploinsufficient autism susceptibility genes. bioRxiv. 2024, 2024-03. 10.1101\/2024.03.13.584921","journal-title":"bioRxiv"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-022-00608-z","article-title":"Future prospects for epigenetics in autism spectrum disorder","volume":"26","author":"Williams LA","year":"2022","unstructured":"Williams LA, LaSalle JM. Future prospects for epigenetics in autism spectrum disorder. Mol Diagn Ther. 2022, 26:569-79. 10.1007\/s40291-022-00608-z","journal-title":"Mol Diagn Ther"},{"key":"ref53","article-title":"Spinocerebellar ataxia","author":"Bhandari J","year":"2024","unstructured":"Bhandari J, Thada PK, Samanta D. Spinocerebellar ataxia. StatPearls (Internet). StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01605-2","article-title":"CRISPR\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells","volume":"11","author":"He L","year":"2021","unstructured":"He L, Wang S, Peng L, et al.. CRISPR\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells. Transl Psychiatry. 2021, 11:479. 10.1038\/s41398-021-01605-2","journal-title":"Transl Psychiatry"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1422442","article-title":"Spinocerebellar ataxias: from pathogenesis to recent therapeutic advances","volume":"18","author":"Cui ZT","year":"2024","unstructured":"Cui ZT, Mao ZT, Yang R, et al.. Spinocerebellar ataxias: from pathogenesis to recent therapeutic advances. Front Neurosci. 2024, 18:1422442. 10.3389\/fnins.2024.1422442","journal-title":"Front Neurosci"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/cells12071037","article-title":"Gene suppression therapies in hereditary cerebellar ataxias: a systematic review of animal studies","volume":"12","author":"Santos C","year":"2023","unstructured":"Santos C, Malheiro S, Correia M, Dam\u00e1sio J. Gene suppression therapies in hereditary cerebellar ataxias: a systematic review of animal studies. Cells. 2023, 12:1037. 10.3390\/cells12071037","journal-title":"Cells"},{"key":"ref57","article-title":"Duchenne muscular dystrophy","author":"Venugopal V","year":"2024","unstructured":"Venugopal V, Pavlakis S. Duchenne muscular dystrophy. StatPearls (Internet). StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2023.07.007","article-title":"Dual CRISPR-Cas3 system for inducing multi-exon skipping in DMD patient-derived iPSCs","volume":"18","author":"Kita Y","year":"2023","unstructured":"Kita Y, Okuzaki Y, Naoe Y, et al.. Dual CRISPR-Cas3 system for inducing multi-exon skipping in DMD patient-derived iPSCs. Stem Cell Rep. 2023, 18:1753-65. 10.1016\/j.stemcr.2023.07.007","journal-title":"Stem Cell Rep"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/cells11192964","article-title":"CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: advances, challenges and perspectives","volume":"11","author":"Chen G","year":"2022","unstructured":"Chen G, Wei T, Yang H, Li G, Li H. CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: advances, challenges and perspectives. Cells. 2022, 11:2964. 10.3390\/cells11192964","journal-title":"Cells"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.06.006","article-title":"CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein","volume":"30","author":"Egorova TV","year":"2023","unstructured":"Egorova TV, Polikarpova AV, Vassilieva SG, et al.. CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein. Mol Ther Methods Clin Dev. 2023, 30:161-80. 10.1016\/j.omtm.2023.06.006","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1089\/gen.42.05.02","article-title":"First patient dosed with VCTX210, a cell therapy for type 1 diabetes","volume":"42","author":"Philippidis A","year":"2022","unstructured":"Philippidis A. First patient dosed with VCTX210, a cell therapy for type 1 diabetes. Genet Eng Biotechnol News. 2022, 42:5-11. 10.1089\/gen.42.05.02","journal-title":"Genet Eng Biotechnol News"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1101\/2023.09.16.558090","article-title":"Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoprotein","volume":"27","author":"Bevacqua RJ","year":"2023","unstructured":"Bevacqua RJ, Zhao W, Merheb E, Kim SH, Marson A, Gloyn AL, Kim SK. Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoprotein. iScience. 2023, 27:108693. 10.1101\/2023.09.16.558090","journal-title":"iScience"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao R","year":"2024","unstructured":"Tao R, Han X, Bai X, et al.. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology. Front Immunol. 2024, 15:1354825. 10.3389\/fimmu.2024.1354825","journal-title":"Front Immunol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01925-5","article-title":"Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy","volume":"23","author":"Chehelgerdi M","year":"2024","unstructured":"Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, et al.. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024, 23:9. 10.1186\/s12943-023-01925-5","journal-title":"Mol Cancer"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.939090","article-title":"A novel anti-cancer therapy: CRISPR\/Cas9 gene editing","volume":"13","author":"Chen XZ","year":"2022","unstructured":"Chen XZ, Guo R, Zhao C, et al.. A novel anti-cancer therapy: CRISPR\/Cas9 gene editing. Front Pharmacol. 2022, 13:939090. 10.3389\/fphar.2022.939090","journal-title":"Front Pharmacol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1393974","article-title":"Delivering CRISPR to the HIV-1 reservoirs","volume":"15","author":"Gurrola TE","year":"2024","unstructured":"Gurrola TE, Effah SN, Sariyer IK, Dampier W, Nonnemacher MR, Wigdahl B. Delivering CRISPR to the HIV-1 reservoirs. Front Microbiol. 2024, 15:1393974. 10.3389\/fmicb.2024.1393974","journal-title":"Front Microbiol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.24","article-title":"CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape","volume":"24","author":"Wang G","year":"2016","unstructured":"Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther. 2016, 24:522-6. 10.1038\/mt.2016.24","journal-title":"Mol Ther"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-021-01584-2","article-title":"Brain HIV-1 latently-infected reservoirs targeted by the suicide gene strategy","volume":"18","author":"Saeb S","year":"2021","unstructured":"Saeb S, Ravanshad M, Pourkarim MR, et al.. Brain HIV-1 latently-infected reservoirs targeted by the suicide gene strategy. Virol J. 2021, 18:107. 10.1186\/s12985-021-01584-2","journal-title":"Virol J"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3390\/v12010084","article-title":"Block-and-lock strategies to cure HIV infection","volume":"12","author":"Vansant G","year":"2020","unstructured":"Vansant G, Bruggemans A, Janssens J, Debyser Z. Block-and-lock strategies to cure HIV infection. Viruses. 2020, 12:84. 10.3390\/v12010084","journal-title":"Viruses"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.821190","article-title":"Biallelic, selectable, knock-in targeting of CCR5 via CRISPR-cas9 mediated homology directed repair inhibits HIV-1 replication","volume":"13","author":"Scheller SH","year":"2022","unstructured":"Scheller SH, Rashad Y, Saleh FM, et al.. Biallelic, selectable, knock-in targeting of CCR5 via CRISPR-cas9 mediated homology directed repair inhibits HIV-1 replication. Front Immunol. 2022, 13:821190. 10.3389\/fimmu.2022.821190","journal-title":"Front Immunol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11080891","article-title":"Application of CRISPR-Cas9 gene editing for HIV host factor discovery and validation","volume":"11","author":"Cisneros WJ","year":"2022","unstructured":"Cisneros WJ, Cornish D, Hultquist JF. Application of CRISPR-Cas9 gene editing for HIV host factor discovery and validation. Pathogens. 2022, 11:891. 10.3390\/pathogens11080891","journal-title":"Pathogens"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.17.541156","article-title":"Epigenome editing durability varies widely across cardiovascular disease target genes","volume":"43","author":"Whittaker MN","year":"2023","unstructured":"Whittaker MN, Testa LC, Quigley A, et al.. Epigenome editing durability varies widely across cardiovascular disease target genes. Arterioscler Thromb Vasc Biol. 2023, 43:2075-7. 10.1101\/2023.05.17.541156","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.101","article-title":"Genome editing with CRISPR\/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome","volume":"26","author":"Xie C","year":"2016","unstructured":"Xie C, Zhang YP, Song L, et al.. Genome editing with CRISPR\/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome. Cell Res. 2016, 26:1099-111. 10.1038\/cr.2016.101","journal-title":"Cell Res"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade1105","article-title":"Ablation of CaMKII\u03b4 oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease","volume":"379","author":"Lebek S","year":"2023","unstructured":"Lebek S, Chemello F, Caravia XM, et al.. Ablation of CaMKII\u03b4 oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science. 2023, 379:179-85. 10.1126\/science.ade1105","journal-title":"Science"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310510","article-title":"An update on MYBPC3 gene mutation in hypertrophic cardiomyopathy","volume":"24","author":"Tudurachi BS","year":"2023","unstructured":"Tudurachi BS, Z\u0103voi A, Leonte A, et al.. An update on MYBPC3 gene mutation in hypertrophic cardiomyopathy. Int J Mol Sci. 2023, 24:10510. 10.3390\/ijms241310510","journal-title":"Int J Mol Sci"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.889519","article-title":"Deciphering common long QT syndrome using CRISPR\/Cas9 in human-induced pluripotent stem cell-derived cardiomyocytes","volume":"9","author":"Song Y","year":"2022","unstructured":"Song Y, Zheng Z, Lian J. Deciphering common long QT syndrome using CRISPR\/Cas9 in human-induced pluripotent stem cell-derived cardiomyocytes. Front Cardiovasc Med. 2022, 9:889519. 10.3389\/fcvm.2022.889519","journal-title":"Front Cardiovasc Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31286-4","article-title":"CRISPR-Cas9 editing of TLR4 to improve the outcome of cardiac cell therapy","volume":"13","author":"Schary Y","year":"2023","unstructured":"Schary Y, Rotem I, Caller T, et al.. CRISPR-Cas9 editing of TLR4 to improve the outcome of cardiac cell therapy. Sci Rep. 2023, 13:4481. 10.1038\/s41598-023-31286-4","journal-title":"Sci Rep"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-023-10380-9","article-title":"Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy","volume":"29","author":"Wu D","year":"2024","unstructured":"Wu D, Chen W. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy. Heart Fail Rev. 2024, 29:511-21. 10.1007\/s10741-023-10380-9","journal-title":"Heart Fail Rev"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab788","article-title":"Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors","volume":"49","author":"Krishnamurthy S","year":"2021","unstructured":"Krishnamurthy S, Traore S, Cooney AL, et al.. Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors. Nucleic Acids Res. 2021, 49:10558-72. 10.1093\/nar\/gkab788","journal-title":"Nucleic Acids Res"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101544","article-title":"Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells","volume":"5","author":"Bulcaen M","year":"2024","unstructured":"Bulcaen M, Kortleven P, Liu RB, et al.. Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells. Cell Rep Med. 2024, 5:101544. 10.1016\/j.xcrm.2024.101544","journal-title":"Cell Rep Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21559-9","article-title":"Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins","volume":"12","author":"Chen L","year":"2021","unstructured":"Chen L, Park JE, Paa P, et al.. Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins. Nat Commun. 2021, 12:1384. 10.1038\/s41467-021-21559-9","journal-title":"Nat Commun"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607137","article-title":"Orkambi\u00ae and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue","volume":"9","author":"Molinski SV","year":"2017","unstructured":"Molinski SV, Ahmadi S, Ip W, et al.. Orkambi\u00ae and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. EMBO Mol Med. 2017, 9:1224-43. 10.15252\/emmm.201607137","journal-title":"EMBO Mol Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore JD","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, et al.. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021, 385:493-502. 10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101741","article-title":"Gene editing as the future of cardiac amyloidosis therapeutics","volume":"48","author":"Sethi Y","year":"2023","unstructured":"Sethi Y, Mahtani AU, Khehra N, et al.. Gene editing as the future of cardiac amyloidosis therapeutics. Curr Probl Cardiol. 2023, 48:101741. 10.1016\/j.cpcardiol.2023.101741","journal-title":"Curr Probl Cardiol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210104119","article-title":"Precision genome editing in the eye","volume":"119","author":"Suh S","year":"2022","unstructured":"Suh S, Choi EH, Raguram A, Liu DR, Palczewski K. Precision genome editing in the eye. Proc Natl Acad Sci U S A. 2022, 119:e2210104119. 10.1073\/pnas.2210104119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce EA","year":"2024","unstructured":"Pierce EA, Aleman TS, Jayasundera KT, et al.. Gene editing for CEP290-associated retinal degeneration. N Engl J Med. 2024, 390:1972-84. 10.1056\/NEJMoa2309915","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/s41649-018-0056-x","article-title":"Risks and benefits of human germline genome editing: an ethical analysis","volume":"10","author":"Rubeis G","year":"2018","unstructured":"Rubeis G, Steger F. Risks and benefits of human germline genome editing: an ethical analysis. Asian Bioeth Rev. 2018, 10:133-41. 10.1007\/s41649-018-0056-x","journal-title":"Asian Bioeth Rev"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1007\/s41649-022-00234-1","article-title":"Mapping the 'ethical' controversy of human heritable genome editing: a multidisciplinary approach","volume":"15","author":"Pougnet R","year":"2023","unstructured":"Pougnet R, Derbez B, Troadec MB. Mapping the 'ethical' controversy of human heritable genome editing: a multidisciplinary approach. Asian Bioeth Rev. 2023, 15:189-204. 10.1007\/s41649-022-00234-1","journal-title":"Asian Bioeth Rev"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2018-105084","article-title":"Moral reasons to edit the human genome: picking up from the Nuffield report","volume":"45","author":"Gyngell C","year":"2019","unstructured":"Gyngell C, Bowman-Smart H, Savulescu J. Moral reasons to edit the human genome: picking up from the Nuffield report. J Med Ethics. 2019, 45:514-23. 10.1136\/medethics-2018-105084","journal-title":"J Med Ethics"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1093\/jlb\/lsz010","article-title":"CRISPR'd babies: human germline genome editing in the 'He Jiankui affair'","volume":"6","author":"Greely HT","year":"2019","unstructured":"Greely HT. CRISPR'd babies: human germline genome editing in the 'He Jiankui affair'. J Law Biosci. 2019, 6:111-83. 10.1093\/jlb\/lsz010","journal-title":"J Law Biosci"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.3906\/biy-1912-52","article-title":"Bioethical issues in genome editing by CRISPR-Cas9 technology","volume":"44","author":"Ayano\u011flu FB","year":"2020","unstructured":"Ayano\u011flu FB, El\u00e7in AE, El\u00e7in YM. Bioethical issues in genome editing by CRISPR-Cas9 technology. Turk J Biol. 2020, 44:110-20. 10.3906\/biy-1912-52","journal-title":"Turk J Biol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1002\/jex2.111","article-title":"CRISPR delivery with extracellular vesicles: promises and challenges","volume":"2","author":"Berggreen AH","year":"2023","unstructured":"Berggreen AH, Petersen JL, Lin L, Benabdellah K, Luo Y. CRISPR delivery with extracellular vesicles: promises and challenges. J Extracell Biol. 2023, 2:111-83. 10.1002\/jex2.111","journal-title":"J Extracell Biol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1444437","article-title":"Advances in delivery systems for CRISPR\/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles","volume":"15","author":"Song Z","year":"2024","unstructured":"Song Z, Tao Y, Liu Y, Li J. Advances in delivery systems for CRISPR\/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles. Front Immunol. 2024, 15:1444437. 10.3389\/fimmu.2024.1444437","journal-title":"Front Immunol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo C","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023, 11:1143157. 10.3389\/fbioe.2023.1143157","journal-title":"Front Bioeng Biotechnol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052456","article-title":"Current strategies for increasing knock-in efficiency in CRISPR\/Cas9-based approaches","volume":"25","author":"Leal AF","year":"2024","unstructured":"Leal AF, Herreno-Pach\u00f3n AM, Benincore-Fl\u00f3rez E, Karunathilaka A, Tomatsu S. Current strategies for increasing knock-in efficiency in CRISPR\/Cas9-based approaches. Int J Mol Sci. 2024, 25:2456. 10.3390\/ijms25052456","journal-title":"Int J Mol Sci"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0971-7","article-title":"CRISPR\/Cas9 \u03b2-globin gene targeting in human hematopoietic stem cells","volume":"567","author":"Dever DP","year":"2019","unstructured":"Dever DP, Bak RO, Reinisch A, et al.. CRISPR\/Cas9 \u03b2-globin gene targeting in human hematopoietic stem cells. Nature. 2019, 567:491-5. 10.1038\/s41586-019-0971-7","journal-title":"Nature"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1038\/srep20070","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"6","author":"Su S","year":"2016","unstructured":"Su S, Hu B, Shao J, et al.. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016, 6:20070. 10.1038\/srep20070","journal-title":"Sci Rep"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411810","article-title":"Hypoimmunogenic human pluripotent stem cells as a powerful tool for liver regenerative medicine","volume":"24","author":"Trionfini P","year":"2023","unstructured":"Trionfini P, Romano E, Varinelli M, et al.. Hypoimmunogenic human pluripotent stem cells as a powerful tool for liver regenerative medicine. Int J Mol Sci. 2023, 24:11810. 10.3390\/ijms241411810","journal-title":"Int J Mol Sci"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2018.09.006","article-title":"Transient retrovirus-based CRISPR\/Cas9 all-in-one particles for efficient, targeted gene knockout","volume":"13","author":"Knopp Y","year":"2018","unstructured":"Knopp Y, Geis FK, Heckl D, et al.. Transient retrovirus-based CRISPR\/Cas9 all-in-one particles for efficient, targeted gene knockout. Mol Ther Nucleic Acids. 2018, 13:256-74. 10.1016\/j.omtn.2018.09.006","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref100","article-title":"Improved cell line development using Cas9-mediated homologous recombination","volume":"10","author":"Liu J","year":"2015","unstructured":"Liu J, Gaj T, Wallen MC, et al.. Improved cell line development using Cas9-mediated homologous recombination. PLoS One. 2015, 10:e0124936.","journal-title":"PLoS One"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-023-02561-1","article-title":"Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells","volume":"142","author":"Hunt JM","year":"2023","unstructured":"Hunt JM, Samson CA, Rand AD, Sheppard HM. Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum Genet. 2023, 142:705-20. 10.1007\/s00439-023-02561-1","journal-title":"Hum Genet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/418885-clustered-regularly-interspaced-short-palindromic-repeats-crispr-cas-unleashed-transforming-gene-editing-with-breakthroughs-applications-and-ethical-dilemmas","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:43:21Z","timestamp":1762015401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/418885-clustered-regularly-interspaced-short-palindromic-repeats-crispr-cas-unleashed-transforming-gene-editing-with-breakthroughs-applications-and-ethical-dilemmas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":101,"URL":"https:\/\/doi.org\/10.7759\/cureus.95908","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}